Biotech, you may not be in position to answer this but Ill ask...

Biotech, you may not be in position to answer this but Ill ask anyway...

why hasn't your company decided to purchase ADO's products if they can achieve a 30%+ cost saving on the plates?

Is it because change in supplier (or change generally) is slow in the medical arena?

I believe in the disruptive story of ADO and it is a potential game changer for pathology labs and beyond.

The unknown I guess is the pace of change (and therefore revenue streams from direct product selling and royalties from large third party contracts)

Its all a waiting game. but my bet is it will just take a couple of large companies to make the change to mix n go and small and medium companies will follow.

Exciting times for ADO (and shareholders)

Maddoc